Immune Design CS (NASDAQ:IMDZ) shares traded 0% up during most recent session to reach at the closing price of $5.84. The stock exchanged hands 723394 shares versus average trading capacity of 1.02 Million shares, yielding a market cap of $281.31 Million. Wall Street analysts covering the stock are projecting that the stock will reach $5.88 within the next 52-weeks. The mean target projections are based on 5 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Immune Design CS (NASDAQ:IMDZ) high price target of $6 and with a conservative view have low price target of $5.85.

RBC Capital “Downgrades” Immune Design CS (NASDAQ:IMDZ) in a research note issued to investors on 2/22/19 to Sector Perform with price target of $6.

Additionally on 10/12/18 H.C. Wainwright “Maintained” Immune Design CS (NASDAQ:IMDZ) to Buy setting price target at $7.8 and on 8/29/18 H.C. Wainwright “Initiates Coverage On” the stock to Buy at $11. Furthermore on 10/18/17 Wells Fargo “Maintained” the stock to Market Perform at $10.

On the other hand the company has Relative Strength Index (RSI 14) of 93.78 along with Average True Range (ATR 14) of 0.15, Consequently Immune Design CS (NASDAQ:IMDZ)’s weekly and monthly volatility is 0.24%, 1.34% respectively. The company’s beta value is at 3.46.

In terms of Buy, Sell or Hold recommendations, Immune Design CS (NASDAQ:IMDZ) has analysts’ mean recommendation of 2.8. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to analysts Immune Design CS (NASDAQ:IMDZ)’s minimum EPS for the current quarter is at $-0.33 and can go high up to $-0.25. The consensus mean EPS for the current quarter is at $-0.29 derived from a total of 3 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.28 earnings per share for the same quarter during last year.

Previously Immune Design CS (NASDAQ:IMDZ) reported $-0.29 earnings per share (EPS) for the quarter, meeting the consensus estimate of $-0.29 by $0. The company posted an earnings surprise of 0%.

Currently Immune Design CS (NASDAQ:IMDZ)’s shares owned by insiders are 0.9%, whereas shares owned by institutional owners are 81.7%. However the six-month change in the insider ownership was recorded -68.15%, as well as three-month change in the institutional ownership was recorded 5.71%.

Immune Design CS (NASDAQ:IMDZ)’s trailing twelve month revenues are $2.2 Million, whereas its price to sales ratio for the same period is 127.87. Its book value per share for the most recent quarter is $2.17 while its price to book ratio for the same period is 2.69, as for as the company’s cash per share for the most recent quarter is $2.23, however its price to cash per share ratio for the same period is 2.62. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.